PROSEEK
To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease
The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a specific enzyme called “Abl” (an enzyme is a biological molecule that accelerates certain chemical reactions in the body). Research has shown that over activation of Abl may play a role in the progression of Parkinson’s disease. Therefore, by limiting or blocking Abl, it may be possible to slow the progression of PD.
Inclusion Criteria:
- Are 50 years or older
- Have been diagnosed with PD with symptoms beginning in the past three years
- Have not taken PD medication for more than 30 days at any time in the past
What to Expect:
- Study-related care
- Study visits
- Study drugs (investigational drug or placebo)
To learn more contact:
Dr Anupama Kale
Heather Macnamara
hmacnamara@dentinstitute.com or 716-819-4117
The investigational drug is not approved by Health Authorities including the US Food and Drug Administration (FDA) for the treatment of Parkinson’s disease
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.